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Abstract
Betulin (lup-20(29)-ene-3b, 28-diol) is a naturally occurring triterpene, which is found in substantial amounts from the outer
bark of birch trees. A library of 51 structurally diverse semisynthetic betulin derivatives was screened against five bacterial
strains, Enterobacter aerogenes, Escherichia coli, Enterococcus faecalis, Pseudomonas aeruginosa, Staphylococcus aureus and a
fungal strain Candida albicans, using broth microdilution assays. Primary antimicrobial screening at 50 mM concentration led
to the identification of five compounds showing antimicrobial properties (inhibition of growth by .70% against one or
more microbial strains). According to the dose-response results, 28-O-(N-acetylanthraniloyl)betulin (compound 5) was the
most active, showing MIC90 of 6.25 mM against two Gram-positive bacteria, E. faecalis and S. aureus. However, the activity of
this compound was affected by albumin binding, which was demonstrated by the loss of activity in a host-pathogen co-
culture assay as well as in the antibacterial assay in the presence of increased concentration of albumin. Furthermore, the
effects on mammalian cells were evaluated by cytotoxicity assessment on hepatocyte cell culture after 24 h exposure to the
compounds. Betulinic aldehyde (18), betulin-28-oxime (31) and hetero cycloadduct with acetoxy groups at carbon atoms 3
and 28 and ethyl substituent at the triazolo ring (43) displayed cytotoxicity towards hepatocytes, with IC50 values of 47, 25
and 16 mM, respectively. The IC50 value for 28-O-(N-acetylanthraniloyl)betulin (5) was 56 mM. The current study presents an
insight into using betulin scaffold for developing derivatives with antibacterial potential, and furthermore the necessity of
in-depth analysis of found actives through selectivity profiling and follow-up studies including in silico ADMET predictions.
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Introduction
According to the World Health Organisation (WHO), infectious
and parasitic diseases account for two to five of the top ten causes
of deaths in the world. The need for new antimicrobials has been
recognised by the WHO, the European Centre for Disease
Control and Prevention, as well as by the European Medicines
Agency. In 2009, the WHO declared antibiotic resistance as one of
the three foremost threats to public health. Therefore, the theme
of the World Health Day, 2011 was ‘‘antimicrobial resistance: no
action today and no cure tomorrow’’ [1–3]. Bacterial infections
alone are the cause of around two million deaths globally and it is
estimated that bacterial pathogens probably infect more than one-
third of the population around the world [4].
Novel medicinal lead compounds are sought by assaying large
compound collections, which can be retrieved from natural
sources or produced by synthetic chemistry. For decades the
majority of drugs have been discovered from natural products:
34% of new small-molecules introduced as drugs worldwide
during 1981–2010 can be traced to, or were inspired by, natural
products [5]. Natural products are recognised as good sources of
scaffolds, which can be employed for generating focused,
semisynthetic libraries. One potential scaffold is betulin (lup-
20(29)-ene-3b, 28-diol), (Fig. 1, compound 1), a pentacyclic
triterpenoid possessing a lupane skeleton. The main source of
betulin are birch trees (Betula sp., Betulaceae), which are
widespread in the northern latitudes of the world. Noteworthy,
there is presently no considerable use of this readily isolable
compound. The betulin content of the outer part of bark is ranging
up to 35%, depending on the birch species, site of ground,
conditions and the age of a tree [6]. Moreover, it has been
estimated that pulp mill producing 200000 t/a of birch kraft pulp
could theoretically produce 3000 t/a of betulin [7].
Birch trees have been widely used as folk remedies, in particular
for their wound healing properties [8]. The birch bark oil is also
used to treat the skin diseases i.e. eczema and psoriasis [9].
Moreover, the white birch bark has been used by Native
Americans to prepare teas and other beverages to treat digestive
tract infections [10].
Betulin, the main constituent of birch trees, has been
investigated previously for its various biological properties, and
has been found to possess a broad range of activities. Amongst
those are antiseptic, anti-inflammatory, antiviral properties, as well
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as antibacterial, antifungal and antitumour activities [8,11,12].
Antimicrobial activity of betulin and its derivatives have been
reported against Streptococcus pyogenes with a minimum inhibitory
concentration (MIC) of 85 mg/mL, and considerable activity has
also been observed against other bacteria, such as Escherichia coli,
Staphylococcus aureus, and Enterococcus faecalis [11,13]. They have
been also found to possess significant antifungal activities against
two Candida species, Candida albicans and Candida krusei [12]. One of
the most interesting derivative, betulinic acid (compound 19,
Table S1) has been previously reported for its antimalarial, anti-
inflammatory, antioxidant, antiprotozoal, anthelmintic, and anti-
fungal activities [14–16]. It has also been considered for its anti-
HIV activity, as well as for specific cytotoxicity against various
tumour cell lines [17,18]. However, it has been found to possess
only mild antibacterial activity against Bacillus subtilis and E. coli
[19].
This study presents the antimicrobial properties of semisynthetic
betulin derivatives against six different microbial strains, supported
by a series of selectivity and follow-up studies, in order to evaluate
the true potential of the most active derivatives as leads for
antibacterial drug development. These studies included in silico
prediction of ADMET properties to assess and prioritise the most
promising compounds for further hit to lead optimisation process.
Materials and Methods
Betulin derivative library
The chemical synthesis and characterisation of the 51 betulin
derivatives (chemical structures are presented in the Tables S1 and
S2) screened in this study have been previously reported [20,21].
10 mM stock solutions of tested samples were prepared in 100%
dimethyl sulphoxide (DMSO, Merck) and stored at 220uC. For
the assays, stock solutions were diluted with the assay media. The
final DMSO concentration in the experiments was 0.5–2.0%, and
did not have any effect on the growth of the tested strains.
Reference compounds
Clinically used antimicrobial agents were selected based on
international guidelines for antimicrobial testing and were utilised
as reference compounds in the antimicrobial assays. The
compounds were purchased from Sigma, Fluka and ICN
Biomedicals. Stock solutions of the reference compounds were
prepared either in double distilled sterile MilliQ water or in
DMSO. Water solutions were sterilised through a 0.22 mm filter
(VWR International). Before the primary antimicrobial screening,
dose-response experiments were carried out in order to determine
the MIC90 of the reference compounds towards their target
strains, and to validate the assay performance (MIC90 values are
presented in Table 1). During the primary screening, these
reference compounds were used as positive controls at the
determined MIC on every plate.
Figure 1. Chemical structures of betulin and the most active betulin derivatives. Betulin (1), betulinyl 28-carboxymethoxycarvacrolate (4),
28-O-(N-acetylanthraniloyl)betulin (5), betulinic aldehyde (18), betulonic acid (23), betulin-28-oxime (31), and heterocyclic derivatives with 1,3-
dioxol-5-yl (35), 3-nitrophenyl (38) and ethyl (43) attached to the nitrogen atom in the triazolo ring.
doi:10.1371/journal.pone.0102696.g001
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Microbial strains and culture conditions
Gram-negative strains Escherichia coli (ATCC 25922), Enterobacter
aerogenes (ATCC 13048) and Pseudomonas aeruginosa (ATCC 27853),
Gram-positive strains Staphylococcus aureus (ATCC 25923) and
Enterococcus faecalis (ATCC 29212), and fungal strain Candida
albicans (ATCC 90028) were obtained from Microbiologics Inc.,
and used for the antimicrobial screening. Strains were selected
according to the guidelines set for clinical laboratories by Clinical
and Laboratory Standards Institute [CLSI, formerly National
Committee on Clinical Laboratory Standards [22]] and the
European Committee on Antimicrobial Susceptibility Testing
(EUCAST). Bacterial strains were grown on Mueller Hinton II
Agar (MHA) (BBL, BD) and Mueller Hinton II broth (MHB)
(BBL, BD), whereas Candida was initiated on Sabouraud Dextrose
Agar (SDA) (Difco, BD) plates. Media were prepared into MilliQ
water according to manufacturer’s instruction and autoclaved at
121uC for 15 min. Bacteria were plated on MHA plates and
incubated at 37uC for 16–18 h. Bacterial suspension for the assays
was prepared by subculturing the bacteria into MHB and by
incubating at 37uC for 16–20 h at 110 rpm prior to the assay.
Candida strain was grown on SDA plates at 27uC for 16–18 h and
suspended into sterile 0.9% saline for the assay.
Mammalian cell lines and culture conditions
Huh-7 cells (derived from human hepatocellular carcinoma)
were obtained as a gift from Prof. Ralf Bartenschlager (University
of Heidelberg, Germany) and used for assessing the cytotoxicity
against mammalian cells. HL cells (a heteroploid cell line used for
propagating respiratory viruses) were used as a host cell line in the
host-pathogen co-culture assay. Huh-7 cells were maintained in
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with
10% fetal bovine serum (FBS, Gibco), 100 mM non-essential
amino acids, 2 mM L-glutamine and 100 IU/mL of penicillin and
100 mg/mL of streptomycin. HL cells were maintained in RPMI-
1640 medium supplemented with 7.5% of FBS (Lonza), 2 mM L-
glutamine, and 100 IU/mL of penicillin and 100 mg/mL
streptomycin. Both cell lines were cultured at 37uC, 5% CO2
and 95% humidity.
Microdilution assay to assess the antimicrobial activity
Antimicrobial screening assays were performed by broth
microdilution method following the guidelines of CLSI and
EUCAST. Bacterial suspensions were prepared as mentioned
earlier and diluted with MHB to obtain a final inoculum of 56105
colony-forming units (cfu)/mL in the assay for all the bacteria
(based on OD620 values previously calibrated against plate counts).
Candida suspension was prepared into sterile 0.9% saline solution
as stated earlier. The suspension was adjusted to yield final
inoculum of 2.56103 cfu/mL by diluting into RPMI-1640 media
(with L-glutamine, w/o NaHCO3 and supplemented with 2%
glucose and 0.165 M MOPS, pH 7; Lonza). Assays were carried
out in clear 96-well microtitre plates and initiated by dispensing an
equal volume of microbial suspension and sample solution diluted
into the assay medium into the wells. The plates were incubated
for 24 h at 37uC (for Candida the incubation was at 35uC for 48 h)
with agitation. Absorbance was measured at 620 nm with Victor
plate reader (Wallac 1420, Perkin Elmer) at 0, 4 and 24 h with the
bacteria, and at 0, 24 and 48 h with Candida. The antimicrobial
activity of the samples was calculated from the absorbance values
by comparing to the controls, and expressed as a percentage
inhibition of growth. All the betulin derivatives were first assayed
at the single concentration of 50 mM (two separate experiments,
each with three replicates). Compounds showing inhibitory activity
.70% in the primary screen were selected for dose-response
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experiments to determine the minimum inhibitory concentration
(MIC90) (with two-fold dilution using nine concentrations between
100 and 0.39 mM). The MIC90 value was expressed as the lowest
concentration of compound that inhibited the microbial growth by
.90%. The MIC90 results are means of three replicates from two
separate experiments.
The effect of bovine serum albumin (BSA) on antimicrobial
activity was assessed by using the S. aureus microdilution assay in a
similar manner as described above, but with increasing concen-
trations of BSA, ranging from 0.023 nM to 25 mM [23]. The
concentration of the betulin derivative, compound 5, was 6.25 mM
(the MIC90 against S. aureus).
Host-pathogen co-culture assay
Betulin derivatives with promising antimicrobial activity in the
primary screening were assayed with host-pathogen co-culture
assay previously described by Kleymann & Werling [24]. Briefly,
HL cells used as the host cell were seeded at 40000 cells/well on
black-walled microplates (Perkin Elmer) and incubated at 37uC,
5% CO2 and 95% humidity for 24 h. Cell monolayers were
infected with 2000 cfus of S. aureus in RPMI 1640 media without
antibiotics. Compounds were added to the media at different
concentrations selected on the basis of the MIC determinations.
Ciprofloxacin was used as a positive control. Co-cultures were
incubated for 3 days at 37uC, 5% CO2 and 95% humidity.
Following the incubation period the cells were washed with
200 mL 6.7 mM PBS, pH 7.4, and finally, 200 mL 6.7 mM PBS,
pH 7.4 containing 10 mg/mL fluorescein diacetate (FDA) was
added to the cells to evaluate the survival of the host cells. After
45 min incubation at room temperature (RT), fluorescence was
measured at 485 nm excitation and 538 nm emission with a
Victor plate reader.
Cytotoxicity against mammalian cells
The effect of the betulin derivatives on metabolic activity of
Huh-7 cells was evaluated by measuring the intracellular ATP
content of the cells after 24 h exposure to the compounds. In brief,
cells were seeded at 20000 cells/well on white-walled microplates
(PerkinElmer) and incubated at 37uC, 5% CO2 and 95%
humidity. After culturing the cells overnight, the medium was
replaced with the assay media (5% FBS) containing the sample
and the cells were incubated for 24 h. Polymyxin B sulphate
(15000 IU/mL) was used as a positive control. Following the
incubation period, Promega’s CellTiter-Glo Cell Viability Assay
was used to determine the intracellular ATP levels according to
the manufacturer’s instructions. Cells were washed with 100 mL
6.7 mM PBS, pH 7.4 and 50 mL of fresh assay media and 50 mL
of the CellTiter-Glo reagent were added into the wells. After
2 min shaking, followed by 10 min incubation at RT, lumino-
metric signal was measured using Varioskan Flash plate reader
(Thermo Fisher Scientific).
Compounds were initially tested at single concentration of
50 mM (n= 3), and based on these results, the most potent
compounds were subjected to the determination of IC50 values.
The IC50 values were calculated by fitting the data from the dose-
response experiments (concentration range between 100 mM and
1.56 mM was selected according to the potency of the compounds)
into sigmoidal dose-response curves by using the Origin software
(OriginLab Corp.).
In silico prediction of ADMET properties and toxicity end-
points
All computational studies were carried out with Discovery
Studio version 3.5 (DS) from Accelrys Discovery Studio (Accelrys
Inc.) using Hewlett Packard computer system (Linux Pentium)
with 2 CPUs. ADMET descriptors protocol in DS uses the
quantitative structure relationship (QSAR) to estimate the human
intestinal absorption, aqueous solubility, blood brain barrier,
cytochrome P450 2D6, hepatotoxicity and plasma protein
binding. Human Intestinal Absorption (HIA) is predicted after
oral administration [25,26]. Intestinal absorption is defined as a
percentage absorbed rather than as a ratio of concentrations. A
well-absorbed compound is one that is absorbed at least 90% into
the bloodstream in humans. Aqueous solubility model uses linear
regression to predict the solubility of each compound in water at
25uC [27]. Blood Brain Barrier model predicts with a quantitative
linear regression, the blood-brain penetration (blood brain barrier,
BBB) after oral administration [25]. The cytochrome P450 2D6
(CYP2D6) model predicts CYP2D6 enzyme inhibition [28].
CYP2D6 is involved in the metabolism of a wide range of
substrates in the liver and its inhibition by a drug constitutes
majority of the cases of drug-drug interaction. The hepatotoxicity
model predicts potential organ toxicity from a wide range of
available literature data of compounds and substances known to
exhibit liver toxicity [29]. The plasma protein-binding model
predicts whether a compound will be highly bound ($90% bound)
to carrier proteins in the blood [30]. TOPKAT (Toxicity
Prediction Komputer Assisted Technology) support assessment
with quantitative structure-toxicity relationship (QSTR) models of
specific toxicological end-points. These include aerobic biode-
gradability, mutagenicity (Ames test), developmental toxicity
potential, rodent carcinogenicity, ocular irritation, skin sensitisa-
tion and rat oral LD50. Aerobic biodegradability model computes
the probability of a query structure to be capable of aerobic
biodegradation [31]. The mutagenicity model has been developed
according the US Environmental Protection Agency (EPA)
Genotox protocol and assesses the probability of a compound
that the query structure represents to be mutagen. The develop-
mental toxicity potential (DTP) modules of TOPKAT assess the
probability of a query structure to be a developmental toxicant in
the rat. Developmental toxicity is any reversible or irreversible
alteration, which affects normal growth or development or
behaviour of biological organism. The rodent carcinogenicity
model computes the probability of a compound that the chemical
query structure represents to be carcinogen. Models that compute
the probability of a compound to be an ocular irritant or a skin
sensitiser were also included in the study. The rat oral LD50
module of the TOPKAT package assesses oral acute median lethal
dose, LD50, in the rat. It comprises QSTR models and
experimental LD50 values for approximately 4000 chemicals.
All the models used were developed with structurally diverse
compounds and their measured ADMET properties. In the
present study ADMET and toxicity profiles for the most active
compounds were studied using their 2D chemical structures as
input to DS.
Results and Discussion
Antimicrobial activity of betulin derivatives
Primary antimicrobial screening of 51 structurally diverse
betulin derivatives showed that five compounds (4, 5, 23, 35,
38) inhibited the growth of Gram-positive bacteria at 50 mM
concentration by .70% (Tables 1, S1 and S2). Of these, 28-O-(N-
acetylanthraniloyl)betulin (5, Fig. 1) was the most active, with .
Betulin Derivatives as Antimicrobial Agents
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90% inhibition of both S. aureus and E. faecalis. Betulonic acid (23)
inhibited the growth of E. faecalis by 74% and S. aureus by 51%.
The active compounds were further evaluated in confirmatory
dose-response experiments, and MIC90 value of 6.25 mM against
both Gram-positive bacteria was determined for compound 5.
With all the other compounds, 90% inhibition was not achieved
even at the highest test concentration 100 mM. Noteworthy,
several betulin derivatives showed activity against E. faecalis; 25
compounds displaying moderate activity (range 50–70%) and five
compounds with inhibition .70% (Fig. 1, Tables S1 and S2). All
heterocyclic betulin derivatives showed some effect against E.
faecalis, the inhibition ranging from 38 to 73% (Table S2) whereas
almost all acetyl derivatives of betulin screened in our study,
especially when the acetyl group was attached to 28-OH
(compounds 14, 15, 16, 21 and 29; Table S1), were inactive
against all microbial strains tested. None of the betulin derivatives
were found to be active against Gram-negative bacteria E. coli, P.
aeruginosa and E. aerogenes, with the exception of betulinic acid (19)
and its methyl ester (20) which showed minor activities (38 and
39% inhibition, respectively) against E. aerogenes. Obviously, this
might be due to the presence of outer membrane in Gram-
negative bacteria, which is an efficient barrier for compound entry,
whereas Gram-positive bacteria lack the outer membrane
structure.
Based on the differences between the derivatives in activity
against Gram-positive bacteria S. aureus and E. faecalis, the
following structure-activity relationships could be observed.
Starting material betulin (1), displayed low activity (20%)
comparing to its dihydro derivative, compound 2 (62%) against
E. faecalis. In addition, increased activity against this particular
microbial strain was displayed by all betulin C28 (R2) monoesters
(3–9): betulinyl 28-carboxymethoxycarvacrolate (4) and 28-O-(N-
acetylanthraniloyl)betulin (5) showed significant effect (72 and
99%, respectively). Furthermore, betulinic acid (19) and its methyl
ester (20) showed moderate activities (56 and 51% inhibition,
respectively) against E. faecalis. Within the group of compounds
21–27 beneficial effect of C3 carbonyl (R1) was observed, with
some of the derivatives showing improved activity against this
Gram-positive strain: dihydrobetulonic acid (24; inhibition 57%),
vanillinyl betulonate (26; 59% inhibition) and betulonic acid (23;
74% inhibition). Nonetheless, methyl ester of betulonic acid (25)
was totally inactive, whereas oxime (30 and 31) and C28 nitrile
derivatives (32 and 33) showed modest activity against E. faecalis
(57, 41, 57, and 49%, respectively).
Interestingly, heterocyclic compounds (34–41) having acetyl
groups at C3 and C28 (R2) with aromatic substituents at N-4 (R1)
displayed slightly increased activity, when compared to heterocy-
clic compounds having bulkier acyl groups at C3 and C28 or
methyl at N-4. Heterocycles with aromatic substituents at N-4,
1,3-dioxol-5-yl (35) and 3-NO2-phenyl (38) displayed the best
activities (70 and 74% inhibition, respectively) in this particular
subgroup (Table S2).
Our findings are in agreement with previous reports in which
low activity has been described for betulin (1) against S. pyogenes
(MIC 85 mg/mL) [11], S. aureus (MIC 0.25 mg/mL), E. coli (MIC
0.25 mg/mL) and P. aeruginosa (MIC 0.25 mg/mL) [32]. Similarly,
betulinic acid (19) has been found to be inactive against S. aureus,
E. coli, B. subtilis and Micrococcus luteus [19,33,34].
Furthermore, Krasutsky et al. have assayed 35 lupane-type
triterpenes (17 allobetulin derivatives, 17 betulin derivatives and 1
lupeol derivative) using Kirk-Bauer disc diffusion method against
E. coli, S. aureus and B. subtilis, as well as 9 lupane derivatives
against S. epidermidis, S. aureus and E. faecalis [35]. Derivatives
consisted mostly of esters (e.g. succinate, phthalate and glutarate),
amides (e.g. glycine, alanine and proline), as well as phosphates
and oxidation products. Betulin, allobetulin and lupeol derivatives
performed very poorly, as only very few showed any activity. In
addition, none of the compounds inhibited B. subtilis even at very
high 10 mg/mL concentration. Evident beneficial effect of C3
carbonyl, observed also in our study, was noted, as lupenon-1,2-
ene-2-ol and lupenone were the most active compounds and
clearly more active than the parent compound lupeol (all having
methyl at C28) against E. coli and S. aureus [35]. In addition,
enhanced antibacterial activity of betulonic acid (23), as well as
dihydrobetulonic acid (24) has been also reported against
Chlamydia pneumoniae, as they performed in the top five compounds
out of 32 betulin derivatives [16].
Other naturally occurring and closely related pentacyclic
triterpenes possessing six-membered E-ring, i.e. ursolic acid
(UA), oleanolic acid (OA) and morolic acid (MA) have also been
studied in similar manner for their antimicrobial potential. UA
and OA have been previously reported to exhibit stronger activity
against S. aureus and E. faecalis than betulinic acid (UA: MIC 4–8;
OA: 8–64; 19 .256 mg/mL). In addition, all three triterpenes
were inactive against E. coli and P. aeruginosa [36]. Gherke et al.
have reported improved activity for MA (MIC$100 mg/mL) after
introduction of C3 carbonyl group (MIC$3.12 mg/mL), when
tested against a panel of seven different bacterial species (B. subtilis,
S. aureus, S. pyogenes, Staphylococcus saprophyticus, E. coli, P. aeruginosa
and Shigella sonnei) [37]. The beneficial effect of C3 carbonyl group
could be partially explained by the crystal structure of these
triterpenes. Betulonic acid (23) in DMSO–water (9:1, v/v)
solvatomorphs reveal that the ring-A with a C3 carbonyl adopts
a flattened twisted-boat conformation, which differs from betulin
derivatives having a C3 hydroxyl group at this position. It has been
speculated, that the orientation of the rings can influence
hydrogen bonding and the other interactions of betulonic acid
(23) [38].
To our knowledge, UA or OA having a C3 carbonyl and C28
carboxyl groups have not been assayed against any bacterial
species, even though both have been used as a starting material in
studies of related derivatives against Mycobacterium tuberculosis [39],
S. aureus and Klebsiella pneumoniae [40]. It would be highly interesting
to investigate their antibacterial properties to further evaluate the
hypothesis of favouring effect of both C3 carbonyl and C28
carboxyl groups in pentacyclic triterpenes.
In this study, the set of 51 betulin derivatives was also tested
against C. albicans. Most of them, including starting material
betulin (1), as well as betulinic acid (19), were inactive but some
beneficial effect could be observed with C28 esters, e.g. betulin
esters 28-O-chrysanthemoylbetulin (3), betulinyl 28-carboxy-
methoxycarvacrolate (4) and 28-O-nicotinoylbetulin (6) showed
minor activities (31–37% inhibition; Table S1). Moreover,
betulinic or betulonic acid derived compounds, i.e. betulinic acid
methyl ester (20), dihydrobetulonic acid (24) and L-aspartyl amide
of betulonic acid (27), displayed modest inhibitory activity against
this fungal strain (inhibitory effects 34–55%). Noteworthy, all
heterocyclic betulin derivatives (34–51; Table S2) were inactive.
Comparable results, presenting low antifungal activity against C.
albicans, have been previously reported for betulin (1) and its
derivatives (i.e. allobetulin and lupeol derivatives) [35] (MIC
250 mg/mL) [12] and (MIC 180 mg/mL) [41].
Despite the numerous reports on the antimicrobial activity
displayed by pentacyclic triterpenoids of lupane skeleton i.e.
betulin and its derivatives, their mechanism of action is still not
fully understood. Sathya Bama et al. have recently reported
significant antimicrobial activity of triterpenoid extract from the
leaves of Tridax procumbens L., with lup-20(29)-en-3b-ol as the most
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active component [42]. Response mechanism to pentacyclic
triterpenoids possessing lupane skeleton was described to involve
changes in membrane permeability arising from the leakage of
reducing sugars and proteins, as well as reduction of respiratory
chain dehydrogenase enzyme’s activity. Noteworthy, among four
tested microbial strains (S. aureus, E. coli, Proteus mirabilis and Vibrio
cholerae), S. aureus was the most susceptible to the treatment with the
active compound [42]. Reported approach presents the great
potential of pentacyclic triterpenoids with an isopropenyl moiety
and simultaneously suggests the possible mode of action for
compounds sharing lupane skeleton, including the derivative 5.
Evaluation of antimicrobial activity in a host-pathogen
co-culture assay
For studying simultaneously the efficacy and tolerability of
antibacterial compounds, an assay based on co-culturing of a
secondary human cell line (HL, derived originally from human
lung) and a pathogen was used. This system mimics natural
bacterial infection, and gives thus more profound information on
the antibacterial potential of test compounds. In the assay, host
cells are incubated in the presence of the test sample and are
infected with bacteria. After 3 days of incubation, the host cell
survival is determined using fluorescein diacetate to measure the
viability of the host cells. As outputs, the assay provides both half-
maximal inhibitory concentrations (IC50) and half-maximal
cytotoxic concentrations (CC50) for the test compound. During
assay validation, both the host cell and the pathogen culturing was
optimised (number of cells used, inoculum size, incubation time;
data not shown). Fig. 2a presents results obtained with the
reference compound, ciprofloxacin.
After assay validation, the host-pathogen co-culture assay was
used to evaluate the antibacterial activity of the two most potent
betulin derivatives, 28-O-(N-acetylanthraniloyl)betulin (5) and
betulonic acid (23). Compounds were assayed at seven different
concentrations in the range of 0.024–100 mM. Surprisingly, no
activity was detected with compound 5, and compound 23 showed
only low activity (27%) at the highest concentration. Data
obtained for compound 5 is displayed in Fig. 2b as an example.
Effect of BSA on antimicrobial activity
As described above, the antimicrobial activities of betulin
derivatives seen in the microdilution assay were not detectable in
the host-pathogen co-culture assay. Since the assay was performed
in cell culture media containing 7.5% of fetal bovine serum, this
was suspected to be the reason. Serum is rich in proteins, the most
abundant of these being albumin. First, we performed the normal
antibacterial assay by replacing the Mueller Hinton II broth with
the cell culture media. This confirmed our hypothesis: no activity
was detected. In order to clearly demonstrate that albumin was
causing the loss of activity, we performed the microdilution assay
by adding BSA at different concentrations together with the active
compounds at MIC90. The activity of compound 5 was clearly
affected by the added BSA: at 24 nM concentration the activity
was reduced by 50% and at concentration 390 nM the activity was
completely lost. As a comparison, the concentration of albumin in
human serum is typically 36–48 g/L which corresponds to 5.42–
7.22 mM concentration. Albumin is capable of interacting with
many organic and inorganic molecules and functions as a key
controller of intercellular fluxes [43–52]. Majority of therapeutic
compounds are reversibly bound to plasma proteins, but the
degree and nature of the binding differs. The degree of binding
between a drug and serum proteins governs its therapeutic
potential and pharmacokinetic performance, and albumin binding
is usually considered as a disadvantage for a drug candidate.
Betulinic acid (19) has been previously reported to bind to human
serum albumin [53], which supports our findings for the derivative
5. Investigations on, for example, the binding affinity of compound
5 to the BSA molecule, would further elucidate the significance of
this feature.
Effects on mammalian cells and in silico predictions of
ADMET properties
In order to further characterise the potential of betulin
derivatives as antibacterial agents, selectivity evaluation between
prokaryotic and eukaryotic cells (cytotoxicity assays on hepatocyte
Huh-7 cell line) and in silico predictions of ADMET properties
were carried out. Measuring the intracellular ATP content is a
very sensitive and common method for evaluating cell viability
after compounds exposure. The cells were exposed to the
compounds for 24 h, which necessitated the use of FBS-containing
cell culture media in the experiment, but the serum concentration
was reduced from 10 to 5% in order to decrease the possible
interference of serum albumin. In the primary testing at 50 mM
concentration, following compounds displayed the highest cyto-
toxicity towards Huh-7 cells: hetero cycloadduct (43; cytotoxicity
85%), betulinic aldehyde (18; cytotoxicity 61%) and betulin-28-
oxime (31; cytotoxicity 61%) (Table 1). Cytotoxicities of 28-O-(N-
acetylanthraniloyl)betulin (5) and betulonic acid (23) were 30 and
18%, respectively. IC50 values were determined for the most
cytotoxic derivatives (18, 31 and 43) and for the most
antibacterially active derivative 5. Polymyxin B sulphate was used
Figure 2. Antimicrobial activity in host-pathogen co-culture assay. The assay was based on S. aureus infected HL cell line. Dose-response
results for a) ciprofloxacin) and b) 28-O-(N-acetylanthraniloyl)betulin (5).
doi:10.1371/journal.pone.0102696.g002
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as a positive control (IC50 of 9361 IU/mL). As could be expected
from the primary results presented in Table 1, three compounds
exhibited clear cytotoxicity: IC50 values of 47, 25 and 16 mM were
measured for compounds 18, 31 and 43 (Fig. 3), respectively. In
addition, the IC50 value of 56 mM for compound 5 was
determined. Conclusions on the selectivity of compound 5 towards
bacteria cannot, however, be made based on this finding. The
presence of 5% serum in the cytotoxicity assay and thus albumin
binding may have influenced the detected cytotoxicity. Further-
more, the ATP assay showed that at higher concentrations
(100 mM), compounds 5, 18 and 43 completely destroyed the cell
monolayer, whereas compound 31 showed only 60% of inhibition.
The cytotoxic effect towards human Huh-7 hepatocyte cells
observed for betulinic aldehyde (18), as well as hetero cycloadduct
(43) is in agreement with previous reports [20,21]. Betulin-derived
compounds have been reported to be cytotoxic towards cancer cell
lines of different histogenetic origin, including drug resistant
tumours [54,55]. For instance, betulinic acid (19) have been shown
to display strongly selective effect against human melanoma cell
lines (A375, 518A2, MES20 and MES21) [56,57] by inducing
apoptosis via the activation of caspases and having direct effects on
mitochondria [55,58–60]. However, its cytotoxicity against
hepatocytes observed in our study was quite low (30% inhibition),
which is in agreement with the previous reports [20] and confirms
that its activity is strongly dependent on the type of cancer cell line
[60]. Noteworthy, in contrast to betulinic acid (19), betulin (1) has
no significant cytotoxic effect against various tumour cell lines
[61], which was also observed in our study (compound 1,
cytotoxicity 14%). In addition, it was previously reported that
oxidation of betulin to betulinic aldehyde (18) results in
significantly increased cytotoxicity against cancer cell lines [55].
Moreover, betulin 3,28-dioxime was cytotoxic against human oral
epidermoid carcinoma (KB), whereas betulinic acid 3-oxime was
inactive, indicating the importance of the suitable substitution
pattern at C28 for the activity [61].
Compound instability in experimental conditions may lead to
loss of activity, or to production of metabolites, which can be more
active than the original compound. Betulin 1 is a stable
compound, as we have not noticed any degradation of samples
even if stored at ambient temperature under air atmosphere for
several years. Moreover, the most unstable chemical bond within
betulin derivatives (Fig. 1), the ester bond, is stable under identical
incubation conditions as demonstrated by Zenger et al. [62] with
succinic acid-bridged tacrine–silibinin co-drug. In addition, other
chemical bonds such as amide and ether were shown to be stable
as well. Thus, instability issues cannot be seen as a major concern
regarding the betulin derivatives of this study.
Prediction of ADMET properties in silico can be a good tool to
further evaluate compounds’ potential and may be used to
eliminate compounds possessing unfavourable characteristics at
early phase in the drug discovery process. This will help later to
optimise and prioritise the most promising compounds for further
hit to lead optimisation. For this reason, we carried out
computational evaluation of ADMET properties [human intesti-
nal absorption (HIA), aqueous solubility, blood brain barrier,
cytochrome P450 2D6 inhibition, hepatotoxicity and plasma
protein binding] and prediction of several toxicity end-points for
the most active compounds. According to the predicted values, the
derivatives differ in their predicted absorption and solubility
properties, but show similar tendency for cytochrome P450 2D6
inhibition, hepatotoxicity, plasma protein binding and toxicity
end-points (Tables S3 and S4). Toxicity potential prediction also
shows some difference between these compounds. The ADMET
plot (Fig. S1) using calculated PSA (polar surface area) versus
AlogP98 properties contains two sets of ellipses, which represent
the prediction confidence space (90% and 99%) for the BBB and
HIA models, respectively. In ADMET plot, for the BBB property,
six of the nine compounds are outside the 99% ellipse (undefined,
Table S3), only two compounds (compound 1 and 18) are inside
the 99% ellipse (high, Table S3). Hence, most of the compounds
Figure 3. Cytotoxic effect of selected betulins on mammalian
cells (Huh-7) after 24 h exposure at different concentrations. A)
betulinic aldehyde (18), B) betulin-28-oxime (31) and C) hetero
cycloadduct (43).
doi:10.1371/journal.pone.0102696.g003
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are most likely not able to penetrate the BBB and the possibility of
CNS side effects are absent. Only the two compounds with high
BBB value represent a possible risk, as they are predicted to easily
cross the BBB. The analysis of the plot for the HIA property
reveals that four compounds (compounds 1, 18, 23, 31) fall inside
the 99% confidence ellipse, whereas the rest of the compounds are
outside. This means that these four compounds possess good HIA.
All compounds are predicted to have low solubility, to be non-
inhibitor of CYP2D6 and without hepatotoxicity. Eight of the nine
compounds (compounds 1 to 38) are predicted to bind highly to
carrier proteins in the blood, which we also observed in the
experiments in the presence of BSA.
Some of the predicted toxicity end-points are resumed in Table
S4. TOPKAT suggests that most of the compounds are aerobically
biodegradable, all are non-mutagen and devoid of any carcino-
genicity, ocular irritancy and skin irritancy. Six of the nine
compounds present developmental toxicity potential (compounds
1 to 31). However, TOPKAT models tend to overestimate the
toxicity of compounds by assigning undetermined value as toxic.
The predicted rat oral LD50 values of all the compounds range
from 0.406 g/kg to 5.130 g/kg. These high LD50 values suggest
that these compounds are lethal only at very high dose. For all
models, an analysis was performed on query compounds before
the prediction, to ensure that they are within the optimum
prediction space in which the model is applicable. All the
compounds are within the optimum prediction space of models.
This analysis gives an indication of the potential effect of these
compounds on certain toxicity end-points. With this information,
selected compounds can be further explored for structural feature
identification and optimization to improve their activity and
toxicity potential. In summary, according to predicted ADMET
properties (Table S3), compounds 23 and 31 can be favoured in
the view of their good predicted properties.
Conclusions
In this study, primary screening and a set of follow-up studies
have been used for evaluating the potential antimicrobial action of
betulin derived compounds. Primary antimicrobial screening
showed that 28-O-(N-acetylanthraniloyl)betulin (5) was the most
active showing MIC90 of 6.25 mM against two Gram-positive
bacteria, E. faecalis and S. aureus. Nevertheless, its activity was
affected by albumin binding, which was demonstrated by loss of
activity in the host-pathogen co-culture assay as well as in the
antibacterial assay in the presence of increased concentration of
albumin. Follow-up cytotoxicity studies, based on ATP measure-
ment of human hepatocyte cell culture after 24 h exposure to the
compounds, showed that three compounds, betulinic aldehyde
(18), betulin-28-oxime (31) and hetero cycloadduct (43) displayed
cytotoxicity towards hepatocytes. This study demonstrated that
introduced modifications to the parent betulin structure can result
in varying level of antibacterial activity and cytotoxicity, and the
right choice of substitution is crucial for the improvement of their
pharmacological properties.
Most importantly, the results demonstrate the significance of
taking a multidimensional approach when studying biological
activities of new compounds. Excluding the follow-up studies
carried out on mammalian cells and in in silico would have given a
very limited view on the real potential of the hits identified in the
antimicrobial screening.
On the other hand, previous reports on combined antibiotic
therapy of triterpenoids, including betulin derivatives (i.e. betulinic
acid and betulinic aldehyde), with commonly available antibiotics
could be also seen as an alternative way for applying compounds
that show relatively modest antimicrobial effects [63]. Pentacyclic
triterpenoids in combination with reference antibiotics could
target different sites in bacteria and in such a way generate either
an additive or synergistic effect, as well as contribute to the delay
in the appearance of antimicrobial resistance.
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